Invention Grant
- Patent Title: Dosing of cabozantinib formulations
-
Application No.: US15126767Application Date: 2015-03-17
-
Publication No.: US10159666B2Publication Date: 2018-12-25
- Inventor: Dana T. Aftab , Sriram Naganathan , Wei Xu , Steven Lacy
- Applicant: Exelixis, Inc.
- Applicant Address: US CA Alameda
- Assignee: Exelixis, Inc.
- Current Assignee: Exelixis, Inc.
- Current Assignee Address: US CA Alameda
- Agency: Honigman Miller Schwartz and Cohn, LLP
- Agent Heidi M. Berven; Jonathan P. O'Brien
- International Application: PCT/US2015/021072 WO 20150317
- International Announcement: WO2015/142928 WO 20150924
- Main IPC: A61K31/47
- IPC: A61K31/47 ; A61K9/20 ; A61K9/00
Abstract:
The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
Public/Granted literature
- US20170087143A1 Dosing of Cabozantinib Formulations Public/Granted day:2017-03-30
Information query
